Skip to content
Screener

AOCI at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.29B+17.0%
Pfizer logo
PfizerPFE
-$7.2B+16.1%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$1.3M-61.1%
Gilead Sciences logo
Gilead SciencesGILD
$95M+628%
Geron logo
GeronGERN
-$339K-390%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$828K-5,420%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.28B+60.1%
Enterprise value$20.34B+53.5%
P/E15.1×-2.4×
P/S4.2×+0.9×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025*
Stockholders’ equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding
Common Stock, $0.001 par value; 400,000,000 shares authorized; 200,977,687 and 198,460,009 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively201198
Additional paid-in capital5,221,8044,928,049
Accumulated other comprehensive income19,71825,462
Retained earnings1,102,704213,769
Total stockholders’ equity6,344,4275,167,478
Total liabilities and stockholders’ equity$7,872,647$6,957,973

Item 1. Financial Statements

FAQ

What is Incyte's AOCI?
Incyte (INCY) reported AOCI of $19.72M in Q2 2026.
How has Incyte's AOCI changed year-over-year?
Incyte's AOCI increased by 46.7% year-over-year, from $13.44M to $19.72M.
What is the long-term trend for Incyte's AOCI?
Over 5 years (2020 to 2025), Incyte's AOCI has grown at a 10.6% compound annual growth rate (CAGR), from -$15.36M to $25.46M.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Ask your AI about Incyte's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude